2016 ASCO Annual Meeting Abstract 8059: Healthcare Costs Among Multiple Myeloma (MM) Patients (Pts) Without Stem Cell Transplant (SCT)

MM Tx medications and tx of MM complications/AEs represent the majority of healthcare costs in MM pts. Monthly MM Tx medication costs were greatest for 4L+ and monthly total costs at treatment initiation were greatest for 1L. In each LOT monthly costs declined over time. Therapies that extend PFS and the treatment-free interval may reduce the costs of MM treatment and likely defer costs of subsequent MM tx.


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.